MetaCap

SAB Biotherapeutics Inc. Company Profile

NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.81-0.10 (-3.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SAB Biotherapeutics at a glance

SAB Biotherapeutics Inc. (NASDAQ: SABS) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Miami Beach, FL. SAB Biotherapeutics is led by Mr. Samuel J. Reich and employs about 86 people. The company's shares have traded publicly since 2021.

At a market capitalization of $253.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001833214, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does SAB Biotherapeutics do?

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Business description based on the company's public filings.

Company information

Legal name
SAB Biotherapeutics Inc.
Ticker
NASDAQ: SABS
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Samuel J. Reich
Employees
86
Headquarters
777 W 41st St., Miami Beach, FL, United States
Phone
305 845 2813
Website
sab.bio
IPO year
2021
Market cap
$253.15M
SEC CIK
0001833214
Latest annual report
10-K · Mar 9, 2026

Companies similar to SAB Biotherapeutics

SABS peer companies
CompanyPrice% ChgMarket capCompare
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs SABS
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs SABS
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs SABS
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs SABS
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs SABS
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs SABS
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs SABS
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs SABS

Related